Evolution of the Average Target: National Health Investors, Inc.

Evolution of the Target Price: National Health Investors, Inc.

Changes in Analyst Recommendations: National Health Investors, Inc.

419fed42.h4eHsr9r5ZuIyoUVGiPrOtb3q3rENNEzP5oqPi1oZ6I.zO7M9_kh1tfA-vJGVGulCIaD_BODfONEVPhJemkqFMbu0dLczV2x_8P8vQ~609dfbdd30023f2af3d2a8a96523eda7
06-25 Deutsche Bank Adjusts National Health Investors Price Target to $80 From $85, Maintains Hold Rating MT
06-12 Truist Lowers Price Target on National Health Investors to $81 From $89, Keeps Buy Rating MT
04-22 Truist Lowers Price Target on National Health Investors to $89 From $92, Keeps Buy Rating MT
03-12 Truist Raises Price Target on National Health Investors to $92 From $85, Keeps Buy Rating MT
01-20 Deutsche Bank Downgrades National Health Investors to Hold From Buy, Adjusts Price Target to $85 From $90 MT
01-20 Truist Raises Price Target on National Health Investors to $85 From $83, Keeps Buy Rating MT
12-15 Truist Adjusts Price Target on National Health Investors to $83 From $81, Maintains Buy Rating MT
01/10/25 Cantor Fitzgerald Initiates Coverage on National Health Investors With Overweight Rating, $90 Price Target MT
15/08/25 Truist Adjusts Price Target on National Health Investors to $81 From $77, Maintains Buy Rating MT
10/07/25 KeyBanc Upgrades National Health Investors to Overweight From Sector Weight, Sets $80 Price Target MT
02/07/25 National Health Investors Shares Rise After Upgrade From Truist MT
02/07/25 Truist Upgrades National Health Investors to Buy From Hold, Maintains $77 Price Target MT
09/06/25 Truist Raises Price Target on National Health Investors to $77 From $76, Keeps Hold Rating MT
18/03/25 Truist Adjusts Price Target on National Health Investors to $76 From $70, Maintains Hold Rating MT
17/01/25 Truist Cuts Price Target on National Health Investors to $70 From $72, Maintains Hold Rating MT
02/01/25 Wedbush Cuts Price Target on National Health Investors to $77 From $87, Keeps Outperform Rating MT
23/12/24 Truist Lowers Price Target on National Health Investors to $72 From $78, Keeps Hold Rating MT
01/10/24 Wells Fargo Downgrades National Health Investors to Equal Weight From Overweight, Adjusts Price Target to $86 From $81 MT
24/09/24 BofA Securities Initiates Coverage on National Health Investors With Buy Rating MT
30/08/24 Truist Securities Adjusts Price Target on National Health Investors to $78 From $65, Maintains Hold Rating MT
27/08/24 Deutsche Bank Raises Price Target on National Health Investors to $90 From $69, Keeps Buy Rating MT
26/06/24 Truist Securities Adjusts Price Target on National Health Investors to $65 From $58, Maintains Hold Rating MT
18/03/24 Wedbush Raises National Health Investors' PT to $66 From $64 After Investor Meetings With Management, Maintains Outperform Rating MT
12/03/24 BMO Capital Upgrades National Health Investors to Outperform From Market Perform MT
26/02/24 Wells Fargo Upgrades National Health Investors to Overweight From Equalweight, Price Target is $63 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+4.1%
-0.29%
+1.79%
-1.45%
+1.35%
+3.84%
+5.3%
+0.06%
+18.52%
+12.7%
Average +4.59%
Weighted average by Cap. +1.14%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
79.26USD
Average target price
82.88USD
Spread / Average Target
+4.56%
High Price Target
91.00USD
Spread / Highest target
+14.81%
Low Price Target
74.00USD
Spread / Lowest Target
-6.64%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Deutsche Bank Securities
Truist Securities
Cantor Fitzgerald
KeyBanc Capital Markets
Wedbush
Wells Fargo Securities
BofA Securities
BMO Capital
Jefferies & Co.
Credit Suisse
Berenberg Bank
Stifel Nicolaus
Capital One Securities
Mizuho Securities
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
79.26USD
Average target price
82.88USD
Spread / Average Target
+4.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NHI Stock
  4. Consensus National Health Investors, Inc.